
Zevra Cashes in on First FDA-Approved NPC Treatment with PRV
Neil F. McFarlane, Zevra Therapeutics President and CEO After gaining FDA approval for Miplyffa® (arimoclomol) as the first-ever therapy indicated to treat Niemann-Pick disease type C (NPC), Zevra Therapeutics has cashed in on the regulatory win by closing …